MB
SLDB icon

MPM BioImpact’s Solid Biosciences SLDB Stock Holding History

MPM BioImpact’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,634,569
Closed -$10.1M – 49
2025
Q3 		$10.1M Hold
1,634,569
– – 1.65% 29
2025
Q2 		$7.96M Sell
1,634,569
-7,787
-0.5% -$27.5K 1.38% 33
2025
Q1 		$6.08M Buy
+1,642,356
New +$7.03M 1.04% 35
2024
Q4 		– Sell
-11,518
Closed -$80.3K – 53
2024
Q3 		$80.3K Buy
+11,518
New +$93.4K 0.01% 43

Other funds holding SLDB

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

MPM BioImpact's SLDB Position: Q4 2025 in Review

MPM BioImpact sold out of Solid Biosciences (SLDB) in Q4 2025, closing a stake of 1,634,569 shares — an estimated $10.1M sold.

MPM BioImpact first reported a position in SLDB in Q3 2024 and held it in 4 quarters. The position peaked at $10.1M in Q3 2025. 130 funds tracked by Wall St. Rank hold SLDB as of Q4 2025.

  • MPM BioImpact reported no remaining Solid Biosciences position as of Q4 2025 after selling out during the quarter.
  • MPM BioImpact sold 1,634,569 Solid Biosciences shares in Q4 2025, an estimated $10.1M.
  • MPM BioImpact first reported a position in Solid Biosciences in Q3 2024 and held it in 4 quarters.
  • MPM BioImpact's Solid Biosciences position peaked at $10.1M in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.